*NO COVER LETTER

980772-5
IPOS COPY.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07D 487/04, A61K 31/55, C07D 495/14, 487/14, 498/04, 471/04, 491/147 // (C07D 487/04, 235:00, 223:00) (C07D 495/14, 333:00, 235:00, 223:00) (C07D 487/14, 235:00, 223:00, 209:00) (C07D 498/04, 267:00, 235:00)

A1

(11) International Publication Number: WO 97/34897

(43) International Publication Date: 25 September 1997 (25.09.97)

(21) International Application Number: PCT/EP97/01264

(22) International Filing Date: 11 March 1997 (11.03.97)

(30) Priority Data:
96200785.5 19 March 1996 (19.03.96) EP
(34) Countries for which the regional or international application was filed: DE et al.

(71) Applicant *(for all designated States except US)*: JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: JANSSENS, Frans, Eduard [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). LEENAERTS, Joseph, Elisabeth [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). SOMMEN, François, Maria [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). SURLERAUX, Dominique, Louis, Nestor, Ghislaine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).


(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.

(54) Title: FUSED IMIDAZOLE DERIVATIVES AS MULTIDRUG-RESISTANCE MODULATORS

(57) Abstract

This invention concerns the compounds of formula (I), the *N*-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dotted line is an optional bond; n is 1 or 2; R^1 is hydrogen; halo; formyl; C_{1-4}alkyl optionally substituted with hydroxy, C_{1-4}alkyloxy, C_{1-4}alkylcarbonyloxy, imidazolyl, thiazolyl or oxazolyl; or a radical of formula -X-COOR^5, -X-CONR^{6}R^7 or -X-COR^{10} wherein -X- is a direct bond, C_{1-4}alkanediyl or C_{2-6}alkenediyl; R^5 is hydrogen, C_{1-12}alkyl, Ar, Het, C_{1-6}alkyl substituted with C_{1-4}alkyloxy, aryl or heteroaryl; R^6 and R^7 each independently are hydrogen or C_{1-4}alkyl; R^2 is hydrogen, halo, C_{1-4}alkyl, hydroxyC_{1-4}alkyl, C_{1-4}alkyloxycarbonyl, carboxyl, formyl or phenyl; R^3 is hydrogen, C_{1-4}alkyl or C_{1-4}alkyloxy; R^4 is hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkyloxy or haloC_{1-4}alkyl; Z is -CH_2-, -CH_2-CH_2-, -CH=CH-, -CHOH-CH_2-, -O-CH_2-, -C(=O)-CH_2- or -C(=NOH)-CH_2-; -A-B- is a bivalent radical; A^1 is a direct bond, optionally substituted C_{1-6}alkanediyl, C_{1-6}alkanediyl-oxy-C_{1-6}alkanediyl, carbonyl, C_{1-6}alkanediylcarbonyl, optionally substituted C_{1-6}alkanediyloxy; A^2 is a direct bond or C_{1-6}alkanediyl; and Q is aryl. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for inhibiting or reversing the effects of multidrug resistance.



(I)